GSK Plc: FDA Accepts Linerixibat NDA For Review

The FDA has accepted GSK's NDA for linerixibat, a targeted inhibitor for treating cholestatic pruritus in patients with primary biliary cholangitis, setting a PDUFA goal date of March 24, 2026. The application is supported by positive Phase III trial data presented at the European Association for the Study of the Liver Congress. Linerixibat is not yet approved in any market.

Analysis

The U.S. Food and Drug Administration (FDA) has accepted GSK plc's New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, intended for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. This acceptance marks a significant regulatory step, with a PDUFA (Prescription Drug User Fee Act) goal date set for March 24, 2026, providing a clear timeline for a potential U.S. market approval decision. GSK's application is substantiated by positive data from the GLISTEN Phase III trial, which was presented in May at the European Association for the Study of the Liver Congress, suggesting a solid clinical basis for the submission. Crucially, linerixibat is not currently approved anywhere globally, indicating that successful FDA review could open up a new therapeutic option and a novel revenue stream for GSK. This development is viewed with moderately positive sentiment for GSK and aligns with key themes of regulatory progression and new product introduction within the healthcare and biotechnology sector.

Key Decisions for Investors

• Investors should monitor GSK's progress towards the PDUFA goal date of March 24, 2026, for linerixibat, as FDA approval could unlock a new market for the company, given the drug is not yet approved elsewhere.
• The positive Phase III GLISTEN trial data underpinning the NDA lends credibility to linerixibat's potential, but the inherent risks of the regulatory approval process warrant careful observation of any updates from the FDA or GSK.
• Consider the potential commercial impact on GSK if linerixibat receives approval, as it would represent a new therapeutic entering the market for cholestatic pruritus in primary biliary cholangitis, a condition with unmet needs.